Tyra Biosciences, Inc. Cash and Restricted Cash
Tyra Biosciences, Inc. (TYRA) had Cash and Restricted Cash of $74.83 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $74.83M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $85.95M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $78.39M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $62.95M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $74.83M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $85.95M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $78.39M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $62.95M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $99.49M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $101.72M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $92.97M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $104.89M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $100.49M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $255.37M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $59.01M 10-K · filed 2026-03-02 |
| 2023-09-30 | $216.65M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $233.41M 10-Q · filed 2024-08-07 |
| 2023-03-31 | $242.70M 10-Q · filed 2024-05-09 |
| 2022-12-31 | $252.21M 10-K · filed 2025-03-27 |
| 2022-09-30 | $264.21M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $276.11M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $293.50M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $302.43M 10-K · filed 2024-03-19 |
| 2021-09-30 | $313.07M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $135.45M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $140.88M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $15.47M 10-K · filed 2023-03-22 |
| 2020-09-30 | $18.07M 10-Q · filed 2021-11-03 |
| 2019-12-31 | $108.00K 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |